Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome

European Journal of Ophthalmology

Volumn 23, Issue 3, 2013, Pages 368-376

  Aragona, Pasquale ^a   Spinella, Rosaria ^a   Rania, Laura ^a   Postorino, Elisa ^a   Sommario, Margherita S ^a   Roszkowska, Anna M ^a   Puzzolo, Domenico ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Clobetasone butyrate; Conjunctival impression cytology; Dry eye; Human leukocyte anti gen DR; Intraocular pressure; Sj gren syndrome

Indexed keywords

CLOBETASONE BUTYRATE; DYE; FLUORESCEIN; HLA DR ANTIGEN; PLACEBO; POVIDONE; UNCLASSIFIED DRUG; VISUCLOBEN; WET COMOD;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EPITHELIUM CELL; FEMALE; HUMAN; IMPRESSION CYTOLOGY; INTRAOCULAR PRESSURE; MALE; OPHTHALMOSCOPY; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SJOEGREN SYNDROME; TEAR FILM; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL SYSTEM EXAMINATION;

ADMINISTRATION, TOPICAL; CLOBETASOL; CONJUNCTIVA; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; FEMALE; GLUCOCORTICOIDS; HLA-DR ANTIGENS; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PHARMACEUTIC AIDS; POVIDONE; PROSPECTIVE STUDIES; SJOGREN'S SYNDROME; TEARS; TREATMENT OUTCOME;

EID: 84876527612     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000229     Document Type: Article

References (35)

1. Lemp MA, Baudouin C, Baum JM, et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 75-92.
2. Tseng SC. Staging of conjunctival squamous metaplasia by impression cytology. Ophthalmology 1985; 92: 728-733.
3. Behrens A, Doyle JJ, Stern L, et al; Dysfunctional Tear Syndrome Study Group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25: 900-907.
4. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004; 138: 444-457.
5. Marsh P, Pflugfelder SC. Topical nonpreserved methylpred-nisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999; 106: 811-816.
6. Sainz de la Maza Serra SM, Simón Castellvi C, Kabbani O. Nonpreserved topical steroids and lacrimal punctal occlusion for severe keratoconjunctivitis sicca. Arch Soc Esp Oftalmol 2000; 75: 751-756.
7. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and non-steroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136: 593-602.
8. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004; 137: 337-342.
9. Pflugfelder SC, Geerling G, Kinoshita S, et al. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 163-178.
10. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000; 11: 478-483.
11. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002; 25: 33-55.
12. Debnath SC, Richards AB. Concentration of clobetasone butyrate in aqueous humour. Br J Ophthalmol 1983; 67: 203-205.
13. Ramsell TG, Bartholomew RS, Walker SR. Clinical evaluation of clobetasone butyrate: a comparative study of its effects in postoperative inflammation and on intraocular pressure. Br J Ophthalmol 1980; 64: 43-45.
14. Vitali C, Bombardieri S, Jonsson R, et al; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
15. Lemp MA. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J 1995; 21: 221-232.
16. Marks R, Barlow JW, Funder JW. Steroid-induced vasocon-striction: glucocorticoid antagonist studies. J Clin Endocrinol Metab 1982; 54: 1075-1077.
17. Klemen UM, Drobec P. Comparison of betamethasone and clobetasone butyrate eye drops and their effect on intraocular pressure (author's transl). Klin Monatsbl Augenheilkd 1981; 179: 33-35.
18. Williamson J, Eilon LA, Walker SR. Clobetasone butyrate eye drops. Effect on ocular inflammation and intraocular pressure. Trans Ophthalmol Soc UK 1981; 101: 27-29.
19. Vaede D, Baudouin C, Warnet JM, Brignole-Baudouin F. Les conservateurs des collyres: vers une prise de conscience de leur toxicité. J Fr Ophtalmol 2010; 33: 505-524.
20. Prabhasawat P, Tseng SC. Frequent association of delayed tear clearance in ocular irritation. Br J Ophthalmol 1998; 82: 666-675.
21. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res 2001; 22: 8-18.
22. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86: 418-423.
23. Tsubota K, Fujihara T, Saito K, Takeuchi T. Conjunctival epithelium expression of HLA-DR in dry eye patients. Ophthalmologica 1999; 213: 16-19.
24. Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 2000; 41: 1356-1363.
25. Brignole-Baudouin F, Baudouin C, Aragona P, et al. A mul-ticentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol 2011; 89: 591-7.
26. Lopin E, Deveney T, Asbell PA. Impression cytology: recent advances and applications in dry eye disease. Ocul Surf 2009; 7: 93-110.
27. Galatoire O, Baudouin C, Pisella PJ, Brignole F. Flow cytom-etry in impression cytology during keratoconjunctivitis sicca:effects of topical cyclosporin A on HLA DR expression. J Fr Ophtalmol 2003; 26: 337-343.
28. Barabino S, Montaldo E, Solignani F, Valente C, Mingari MC, Rolando M. Immune response in the conjunctival epithelium of patients with dry eye. Exp Eye Res 2010; 91: 524-529.
29. Aragona P, Puzzolo D, Micali A, Ferreri G, Britti D. Morphological and morphometric analysis on the rabbit conjunctival goblet cells in different hormonal conditions. Exp Eye Res 1998; 66: 81-88.
30. Aragona P, Micali A, Paladino G, Ferreri F, Puzzolo D. Effects of tear substitutes on conjunctival epithelium of mice. Ophthalmic Res 2007; 39: 265-275.
31. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci 2007; 48: 2553-2560.
32. Aragona P, Romeo G F, Puzzolo D, Micali A, Ferreri G. Impression cytology of the conjunctival epithelium in patients with vernal conjunctivitis. Eye 1996; 10: 82-85.
33. Aragona P, Ferreri G, Micali A, Puzzolo D. Morphological changes of the conjunctival epithelium in contact lens wearers evaluated by impression cytology. Eye 1998; 12: 461-466.
34. Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients. Br J Ophthalmol 2002; 86: 879-884.
35. Marsh P, Pflugfelder SC. Topical nonpreserved methylpred-nisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999; 106: 811-816.